Tuesday, 28 January 2025 04:30 AM
Company Update
The single injection viscosupplementation segment in the Russia Viscosupplementation Market is expected to expand at the fastest and highest CAGR of 5.8% over the forecast period, due to relatively less competition across the product type segments.
NEWARK, DE / ACCESS Newswire / January 28, 2025 / The viscosupplementation market in Russia is poised for significant growth in the coming decade, with sales estimated to climb from USD 55.7 million in 2025 to an impressive USD 97.9 million by 2035, according to market projections. This represents a compound annual growth rate (CAGR) of 5.8% during the forecast period of 2025 to 2035.
The upward trajectory of viscosupplementation sales in Russia reflects an increased demand for non-invasive treatments for osteoarthritis and joint-related disorders. The market already generated notable revenue of USD 52.9 million in 2024, showcasing steady growth fueled by the aging population, greater awareness of viscosupplementation treatments, and advancements in medical technologies.
Viscosupplementation, a minimally invasive procedure that involves injecting hyaluronic acid into the joints to improve lubrication and mobility, is gaining traction as a preferred treatment for individuals seeking alternatives to surgical interventions. With the growing prevalence of osteoarthritis and an emphasis on enhancing patient quality of life, the demand for such treatments is expected to surge in the Russian market.
Get Insights into Market Movements: Request a Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d52552d32383937
Industry analysts predict that favorable healthcare policies and increased healthcare spending in Russia will further bolster the market's growth. Additionally, advancements in product formulations, improved accessibility to treatment, and ongoing research into viscosupplementation are likely to drive innovation and adoption over the forecast period.
As the market moves toward USD 97.9 million by 2035, it presents a promising opportunity for stakeholders, including manufacturers, healthcare providers, and investors, to tap into the burgeoning demand for effective osteoarthritis management solutions.
The viscosupplementation industry in Russia is poised for remarkable growth over the next decade, driven by an aging population, increasing prevalence of osteoarthritis, and advancements in healthcare technology. Viscosupplementation, a minimally invasive procedure used to relieve joint pain, is gaining significant traction due to its efficacy and safety. The trends, challenges, and future opportunities within this dynamic market, providing insights into the industry's outlook from 2025 to 2035.
Rising obesity and ageing population expected to drive the growth of the three injection viscosupplementation segment in Russia
Viscosupplemets are hyaluronic acid doses that are injected in the knee joints for the treatment of osteoarthritis (OA). The rising obesity rate, coupled with a rapidly increasing geriatric population in Russia is giving rise to an increasing number of cases of knee osteoarthritis.
This factor is driving the growth of the single injection viscosupplementation segment in the Russia viscosupplementation market.
Increasing ageing population is another factor that is creating robust development in the Russia viscosupplementation market. Prevalence of osteoarthritis in the adult population in Russia is approximately 13%. Knee osteoarthritis is causing disability in the ageing population in Russia and this is the precise reason for the rise in demand for three injection viscosupplementation.
Three injection viscosupplementation is a cost-effective procedure that reduces the cost burden of knee osteoarthritis patients. Several drugs for three injection viscosupplementation are in the pipeline and this is further creating a positive impact on this segment.
Better patient compliance and reduction in the number of hospital visits is expected to drive the market growth of the three injection viscosupplementation segment over the forecast period.
"Viscosupplementation has emerged as a key player in the treatment landscape for osteoarthritis, particularly among patients seeking effective yet less invasive options for joint pain relief, Russia's growing elderly population, coupled with advancements in healthcare accessibility, is expected to fuel the demand for viscosupplementation in the coming years. The impressive CAGR of 5.8% reflects the sector's potential to address unmet medical needs while aligning with global trends in arthritis care." says Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.
Key Drivers of Growth:
Rising Osteoarthritis Cases
With the prevalence of osteoarthritis on the rise, driven by an aging population and lifestyle factors, the demand for effective treatment options like viscosupplementation is growing. Patients increasingly prefer non-surgical interventions to manage joint pain, creating a favorable environment for market expansion.
Technological Advancements
Innovations in viscosupplementation products, such as long-lasting hyaluronic acid injections, are enhancing treatment outcomes. These advancements make the procedure more accessible and effective, encouraging adoption among patients and healthcare providers.
Healthcare Investments in Russia
The Russian government's commitment to improving healthcare infrastructure and accessibility is a significant factor driving the market. Increased funding for medical facilities and training programs ensures that more practitioners can offer viscosupplementation services, broadening the market reach.
Emerging Trends:
Shift Toward Single-Injection Solutions
Single-injection viscosupplements are becoming increasingly popular due to their convenience and reduced treatment burden. This trend aligns with the growing demand for patient-friendly medical solutions.
Rising Awareness of Joint Health
Public awareness campaigns about joint health and early intervention for osteoarthritis are contributing to increased demand for viscosupplementation. These efforts are expected to drive growth in urban and rural areas alike.
Focus on Personalized Medicine
The industry is leaning towards tailored treatment plans that consider individual patient needs. Personalized viscosupplementation therapies are likely to gain prominence, enhancing treatment satisfaction and outcomes.
Expanding Market Need: Access Our Full Report for In-Depth Analysis and Trends: https://www.futuremarketinsights.com/reports/russia-viscosupplementation-market
Non-consideration of reimbursement by insurance companies in Russia is likely to be a hindrance to the growth in demand for three injection viscosupplementation
The cost of single injection viscosupplementation is lesser than three injection viscosupplementation. Besides, these three injections are available through online portals or can be procured directly from the pharmacists as well.
However, several insurance companies and authorities do not consider these in the reimbursement list of products. Physicians have noted that the formulation of updated treatment guidelines by Osteoarthritis Research Society International (OARSI) for knee osteoarthritis has been restricting the overall outlook on viscosupplementation prescription.
This is expected to lead to increased insurance denials for three injection viscosupplementation. Three injection viscosupplementation is a lengthy procedure wherein patients suffering from osteoarthritis need to take three injections within the span of a certain time period. Owing to these restraints, single injections are expected to gain more popularity in Russia in the years to come.
Challenges to Address:
Despite the promising outlook, the Russia viscosupplementation market faces challenges that could impact growth:
Cost Constraints: High treatment costs may deter widespread adoption, particularly in low-income regions.
Limited Awareness in Rural Areas: Expanding educational outreach and access to viscosupplementation services in remote regions remains a critical challenge.
Regulatory Hurdles: Ensuring compliance with stringent regulatory standards for medical products may pose difficulties for manufacturers.
Market Projections (2025-2035):
Steady CAGR: The viscosupplementation market in Russia is projected to grow at a steady compound annual growth rate (CAGR) during the forecast period, driven by increasing adoption and technological advancements.
Dominance of Hyaluronic Acid Products: Hyaluronic acid-based viscosupplements will likely dominate the market, owing to their proven efficacy in alleviating joint pain.
Urban Centers Leading the Charge: Major urban areas like Moscow and St. Petersburg are expected to witness the highest growth, fueled by better healthcare infrastructure and higher disposable incomes.
Opportunities for Stakeholders:
Expanding Distribution Networks
Companies can capitalize on the untapped potential in rural areas by expanding their distribution networks and investing in educational initiatives.
Collaborations and Partnerships
Strategic alliances with local healthcare providers and institutions can help manufacturers increase their market share and build trust among consumers.
Innovation in Product Offerings
Developing cost-effective, long-lasting, and easy-to-administer products will be key to capturing a larger share of the market.
The viscosupplementation industry in Russia is on the cusp of a transformative decade. With a robust growth trajectory supported by demographic trends, technological advancements, and government initiatives, the market offers lucrative opportunities for stakeholders. By addressing challenges and leveraging emerging trends, the industry can achieve sustained growth and improve the quality of life for countless individuals suffering from joint pain.
As we move toward 2035, the focus on innovation, accessibility, and patient-centered care will undoubtedly shape the future of viscosupplementation in Russia.
Key Players of Viscosupplementation Market:
Anika Therapeutics Inc.
Bioventus LLC
Ferring B.V
Fidia Pharmaceutici S.p.A
MEDA Pharmaceuticals Switzerland GmbH
Sanofi S.A
ZIMMER BIOMET HOLDINGS, INC
Key Segments of Viscosupplementation Market:
By Product:
In terms of product, the industry is divided into- single injection knee hyaluronic acid injections, three injection knee hyaluronic acid injections, five injection knee hyaluronic acid injections and next generation (steroid combination).
By End User:
In terms of end user, the industry is segregated into- hospitals, ambulatory surgical centers, orthopedic clinics, retail pharmacies and online sales.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain:
The global viscosupplementation market size is anticipated to expand at a moderate CAGR of 5.7% during the forecast period. The industry is likely to cross a valuation of USD 3,777.4 million by 2034.
The Europe viscosupplementation market share was projected to be USD 4.49 billion in 2022. By the end of 2023, the market is likely to reach a valuation of USD 4.91 billion. The market for Europe viscosupplementation is expected to garner a 9.37% CAGR and reach a market worth USD 12.03 billion by 2033.
Global demand for interventional cardiology devices is anticipated to record a CAGR of 8.4% during the forecast period (2022 to 2032). The interventional cardiology devices market is expected to be valued at USD 16.4 Billion in 2022 and is likely to reach USD 36.9 Billion by 2032.
The newly released personalized medicine market growth analysis report by Future Market Insights shows that global sales of the Personalized Medicine Market in 2022 were held at USD 326.7 Billion. With a CAGR of 7.8% from 2023 to 2033, the market in the country is expected to reach USD 690.9 Billion.
The sales of artificial pancreas systems in North America and Europe is set to transform diabetes management, with market valuations projected to experience exponential growth. In 2022, the market value of these advanced systems was estimated at USD 182.71 million, with a forecasted surge to USD 567.47 million by 2032, marking an impressive compound annual growth rate (CAGR) of 12% over the decade.
The global at-home testing market trends are estimated to be worth USD 7,789.1 million in 2025 and are anticipated to reach a value of USD 11,877.8 million by 2035. Sales are projected to rise at a CAGR of 4.8% over the forecast period between 2025 and 2035.
The global drug formulation market strategies are estimated to be worth USD 1.7 trillion in 2025 and are anticipated to reach a value of USD 2.8 trillion by 2035. Sales are projected to rise at a CAGR of 5.7% over the forecast period between 2025 and 2035.
The niacin and niacinamide market opportunity is estimated to reach USD 1.3 billion in 2025. It is anticipated to grow at a CAGR of 3.1% during the assessment period 2025 to 2035 and reach a value of USD 1.8 billion by 2035.
The global surgical navigation system market outlook is estimated to be worth USD 1,235.7 million in 2025 and anticipated to reach a value of USD 2,255.2 million by 2035. Sales are projected to rise at a CAGR of 6.2% over the forecast period between 2025 and 2035.
The global organ transport devices market overview are estimated to be worth USD 478.0 million in 2025 and anticipated to reach a value of USD 735.8 million by 2035. Sales are projected to rise at a CAGR of 4.9% over the forecast period between 2025 and 2035.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: [email protected]
Website:https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
SOURCE: Future Market Insights, Inc.